De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice
Journal
Gastroenterología y Hepatología
ISSN
0210-5705
Date Issued
2023
Author(s)
María José Moreta
Ingrid Ordás
Agnès Fernández-Clotet
Berta Caballol
Marta Gallego
Alejandro Vara
Rebeca Barastegui
Angel Giner
Cristina Prieto
Maria Carme Masamunt
Roberto Candia
Elena Ricart
Type
Resource Types::text::journal::journal article
Cite this document
Arenas, A., Moreta, M. J., Ordás, I., Fernández-Clotet, A., Caballol, B., Gallego, M., Vara, A., Barastegui, R., Giner, A., Prieto, C., Masamunt, M. C., Candia, R., & Ricart, E. (2024). De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice. Gastroenterología y Hepatología, 47(7), 673-682. https://doi.org/10.1016/j.gastrohep.2023.07.005
Subjects
anti-tnf
;
crohn's disease
;
discontinuation
;
immunomodulators
;
inflammatory bowel disease
;
ulcerative colitis
;
adult
;
colitis, ulcerative
;
crohn disease
;
drug therapy, combination
;
female
;
humans
;
immunologic factors
;
male
;
middle aged
;
recurrence
;
retrospective studies
;
tumor necrosis factor-alpha
;
adalimumab
;
azathioprine
;
immunomodulating agent
;
infliximab
;
mercaptopurine
;
methotrexate
;
tumor necrosis factor inhibitor
;
ustekinumab
;
vedolizumab
;
immunologic factor
;
tumor necrosis factor
;
adult
;
article
;
clinical practice
;
cohort analysis
;
controlled study
;
crohn disease
;
drug dose intensification
;
drug efficacy
;
drug safety
;
drug withdrawal
;
female
;
follow up
;
human
;
inflammatory bowel disease
;
major clinical study
;
male
;
observational study
;
outcome assessment
;
phenotype
;
protection
;
recurrence risk
;
remission
;
retreatment
;
risk factor
;
therapy de-escalation
;
therapy escalation
;
treatment duration
;
ulcerative colitis
;
combination drug therapy
;
crohn disease
;
drug therapy
;
middle aged
;
recurrent disease
;
retrospective study
;
ulcerative colitis